Mikael Pittet, a cancer immunologist who studies lung cancer at Harvard University Medical School in Boston, is one of Lytix Biopharma’s collaborators. His work was described in an article in Nature Medicine, written by Amanda Keener. The article focus on Pittet`s research on how to make the tumors more likely to respond to immunotherapy. His work with LTX-315 and Lytix Bipharma is also briefly mentioned in the article.

Read the article: